Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 7/20 | 0.38 |
| ▸ | NMT2 | O60551 | 6/20 | 0.38 |
| ▸ | FURIN | P09958 | 4/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23053207 | 0.88 | NMT1 (0.43) | NMT1NMT2FURINSIRT6SIRT1 | |
| SCHEMBL23191800 | 0.86 | NMT1 (0.38) | NMT1NMT2FURINSIRT6SIRT1 | |
| SCHEMBL26003117 | 0.86 | NMT1 (0.38) | NMT1NMT2FURINSIRT6SIRT1 | |
| SCHEMBL24220966 | 0.86 | NMT1 (0.38) | NMT1NMT2FURINSIRT6SIRT1 | |
| SCHEMBL24703967 | 0.86 | NMT1 (0.38) | NMT1NMT2FURINSIRT6SIRT1 | |
| SCHEMBL24220950 | 0.79 | NMT2 (0.32) | NMT1NMT2ITGB3ITGA2B | |
| SCHEMBL23682447 | 0.78 | NMT2 (0.37) | NMT1NMT2FURINSIRT6SIRT1 | |
| SCHEMBL24453587 | 0.78 | NMT2 (0.37) | NMT1NMT2FURINSIRT6SIRT1 | |
| SCHEMBL23191801 | 0.77 | NMT1 (0.40) | NMT1NMT2FURINSIRT6SIRT1 | |
| SCHEMBL24239548 | 0.76 | OPRK1 (0.33) | NMT1NMT2FURINSIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380765-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD. (AU) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380765-A1 | THERAPEUTIC DENDRIMER | CLTA, DCK, CLTB | NMT1 1218/4885NMT2 992/4885FURIN 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.